Valrubicin
Cat. No.：YN310244
CAS No. ：56124-62-0
| 产品名称: | Valrubicin |
| CAS No.: | 56124-62-0 |
| Chemical Name: | pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester |
| Synonyms: | 戊柔比星; AD-32 |
| 分子量: | 723.64 |
| 分子式: | C₃₄H₃₆F₃NO₁₃ |
| SMILES: | CCCCC(OCC([C@]1(O)CC2=C(C(O)=C3C(C4=C(C(C3=C2O)=O)C=CC=C4OC)=O)[C@@H](O[C@H]5C[C@H](NC(C(F)(F)F)=O)[C@H](O)[C@H](C)O5)C1)=O)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Valrubicin 是一种化疗剂，能够抑制 TPA 和 PDBu 诱导的PKC活化，IC50值分别为 0.85 和 1.25 μM，具有抗肿瘤和抗炎作用。 |
| IC50和靶点: | [{name:"TPA-activated PKC:0.85 μM (IC50)"},{name: "PDBu-activated PKC:1.25 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Israel, M., Modest, E.G., and Frei, E., IIIN-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycinCancer Res.35(5),1365-1368(1975)
Niell, H.B., Hunter, R.F., Herrod, H.G., et al.Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell linesCancer Chemother. Pharmacol.19(1),47-52(1987)
Rosada, C., Stenderup, K., de Darkó, E., et al.Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation modelJ. Invest. Dermatol.130(2),455-463(2010)
